➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Express Scripts
Harvard Business School
Mallinckrodt
McKesson

Last Updated: October 28, 2020

DrugPatentWatch Database Preview

Litigation Details for Halozyme, Inc. v. Lee (E.D. Va. 2016)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Biologic Drugs cited in Halozyme, Inc. v. Lee

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Halozyme, Inc. v. Lee (E.D. Va. 2016)

Date Filed Document No. Description Snippet Link To Document
2016-12-19 1 non-statutory obviousness-type double patenting over U.S. Patent Nos. 7,767,429 (claims 9 and 10), 7,846,431 …to receive a patent against Defendant, MICHELLE K, LEE, Director, United States Patent and Trademark ….S. Patent No. 5,766,897, issued June 16, 1998 (“Braxton”); and (c) Thompson et al., U.S. Patent No. …Property ) and Director of the United States Patent and ) Trademark Office, …pursuant to 35 U.S.C. § 145 by the assignee of U.S. Patent Application Serial No. 11/238,171 (“the ’171 Application External link to document
2017-11-13 143 statutory obviousness-type double patenting over U.S. Patent Nos. 7,767,429 (Claims 9 and 10), 7,846,431…of a patent . . . by prohibiting the issuance of the claims in a second patent not patentably distinct…the applicant for patent or (2) a patent granted on an application for patent by another filed…Claim 264 and the ‘429 Patent Claims 9 and 10 Are Patentably Distinct. ...........… The Pending Claims are patently distinct from Claim 6 of the ’081 Patent. [Flamion Test.] External link to document
2018-07-31 173 of U.S. Patent No. 7,767,429 ("the M29 patent") in…seeking reversal of a patent rejection decision issued by the United States Patent and Trademark Office…challenging a final decision issued by the USPTO's Patent Trial and Appeal Board (the "Board")…affirmed the rejections of claims in U.S. Patent Application 11/238,171 ("…December 2016 1:16-cv-01580-CMH-JFA Patent None District Court, E.D. Virginia External link to document
2018-10-23 186 U.S. Patent No. 7,767,429 ("the M29 patent") in view of the U.S. Patent No. …lancu's. Under Secretary of the United States Patent and Trademark Office ("USPTO"), motion…challenging a final decision issued by the USPTC s Patent Trial and Appeal Board (the ^'Board"…the rejections of claims in U.S. Patent Application 11/238,171 ("the … 5,766,897 ("Braxton") and U.S. Patent No. 6,552,170 ("Thompson" External link to document
2017-09-08 96 Exhibit Ex. 1 to M. Kim Decl. double patenting over Claims 9 and 10 of the U.S. Patent No. 7,767,429 (the “’429 Patent”) (A1719…obviousness-type double patenting rejections of the Pending Claims over U.S. Patent Nos. 7,767,429 titled “Soluble…obviousness-type double patenting rejections of the Pending Claims over U.S. Patent Nos. 7,767,429 (claims 9 and…obviousness-type double patenting rejections of the Pending Claims over U.S. Patent Nos. 7,767,429 (claims 9 and…) the Pending Claims are patentable distinct from U.S. Patent Nos. 7,767,429 (claims 9 and External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Dow
Boehringer Ingelheim
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.